Verici Dx plc (LON:VRCI), a developer of advanced clinical diagnostics for organ transplant, has announced that the Company has raised £8.75 million through the Placing announced on 8 October 2026 and the WRAP Retail Offer launched on 9 October 2026.
Following closing of the Fundraising, the Company is pleased to announce that the Capital Access Window has closed, and that trading of the Company’s Ordinary Shares on AIM will be restored with effect from 7:30am today.
Verici Dx has also confirmed, further to the announcements made on 9 October 2026, the result of its Fundraise at the Issue Price of £0.002 pence per share. The Company announces that it has raised aggregate gross proceeds of approximately £250,000 pursuant to the Retail Offer, alongside the previously announced Placing. Accordingly, the Company will issue a total of 124,999,983 new Ordinary Shares at the Issue Price pursuant to the Retail Offer.
In total, the Placing and the Retail Offer have raised gross proceeds of approximately £8.5 million for the Company, via the Placing of 1,683,000,000 Firm Placing Shares, 2,567,000,000 Conditional Placing Shares and the 124,999,983 Retail Offer Shares.
Admission and Total Voting Rights
Applications has been made for the 1,683,000,000 Firm Placing Shares to be admitted to trading on AIM. First Admission is expected to become effective on 13 October 2026. Application will be made for the 2,567,000,000 Conditional Placing Shares and the 124,999,983 Retail Offer Shares to be Admitted to trading on AIM, subject to Share Approval at the General Meeting to be held on 27 October 2026. Second Admission is expected to become effective on or around 28 October 2026.
Upon First Admission, the Company’s issued ordinary share capital will consist of 3,970,311,387 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, from First Admission the total number of Ordinary Shares and voting rights in the Company will be 3,970,311,387. With effect from First Admission, this figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.
The new Ordinary Shares to be issued pursuant to the Placing and the Retail Offer will be issued free of all liens, charges and encumbrances and will, on Admission, rank pari passu in all respects with the new Ordinary Shares to be issued pursuant to the Placing, the Subscription and the Company’s existing Ordinary Shares.
